(Q42449560)

31 October 2017

Tamoxifen inhibits the release of arachidonic acid stimulated by thapsigargin in estrogen receptor-negative A549 cells (English)

1 reference

31 October 2017

1 reference

4

R J Flower

1 reference

31 October 2017

J D Croxtall

1

1 reference

PubMed ID

9434142

31 October 2017

Q Choudhury

series ordinal

2

1 reference

PubMed ID

9434142

31 October 2017

J O White

series ordinal

3

1 reference

31 October 2017

1 November 1997

1 reference

Biochimica et Biophysica Acta

31 October 2017

1 reference

31 October 2017

1349

1 reference

31 October 2017

3

1 reference

31 October 2017

275-284

1 reference

Lipocortin 1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line

31 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

The hepatocyte growth factor receptor kinase-mediated phosphorylation of lipocortin-1 transduces the proliferating signal of the hepatocyte growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Dexamethasone suppression of IL-1 beta-induced cyclooxygenase 2 expression is not mediated by lipocortin-1 in A549 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

The importance of phospholipase-A2 in prostaglandin biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Local variations in protein structure in the human eye lens: a Raman microspectroscopic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Lipocortin-1 and the control of arachidonic acid release in cell signalling. Glucocorticoids (changed from glucorticoids) inhibit G protein-dependent activation of cPLA2 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Characterization and identification of an epidermal-growth-factor-activated phospholipase A2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Lipocortin 1 and the control of cPLA2 activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA2 phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

N-terminal peptide fragments of lipocortin-1 inhibit A549 cell growth and block EGF-induced stimulation of proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Maximal epidermal growth-factor-induced cytosolic phospholipase A2 activation in vivo requires phosphorylation followed by an increased intracellular calcium concentration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen: teaching an old drug new tricks?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Evidence that tamoxifen is a histamine antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen inhibits lipid peroxidation in cardiac microsomes. Comparison with liver microsomes and potential relevance to the cardiovascular benefits associated with cancer prevention and treatment by tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen inhibits 5-lipoxygenase in human polymorphonuclear leucocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen blocks chloride channels. A possible mechanism for cataract formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

The anti-oestrogen drug tamoxifen is an elongation inhibitor of eukaryotic protein biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Differential role of extra- and intracellular calcium in bradykinin and interleukin 1 alpha stimulation of arachidonic acid release from A549 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Calcium antagonism by the antioestrogen tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Tamoxifen reduces calcium currents in a clonal pituitary cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

A novel tumour promoter, thapsigargin, transiently increases cytoplasmic free Ca2+ without generation of inositol phosphates in NG115-401L neuronal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

cPLA2 is phosphorylated and activated by MAP kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Phosphatidylinositol cleavage catalysed by the soluble fraction from lymphocytes. Activity at pH5.5 and pH7.0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Enhanced synthesis de novo of phosphatidylinositol in lymphocytes treated with cationic amphiphilic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

A molecular modeling study of the interactions between the antiestrogen drug tamoxifen and several derivatives, and the calcium-binding protein calmodulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

Anti-angiogenic activity of arachidonic acid metabolism inhibitors in angiogenesis model systems involving human microvascular endothelial cells and neovascularization in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

The estrogen antagonist tamoxifen inhibits carrageenan induced inflammation in LEW/N female rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2760%2897%2900143-4

10.1016/S0005-2760(97)00143-4

7 January 2021

Identifiers

DOI

1 reference

31 October 2017

1 reference

PubMed ID

9434142